Back to All Studies

Myxomatous mitral valve disease is the most common cardiac disease and the leading cause of congestive heart failure in dogs. Reducing blood pressure is one strategy to help manage these patients. By reducing blood pressure, the heart can move blood forward more effectively, reducing fluid accumulation in the lungs that can result from this condition. However, available medications for this health emergency are extremely limited and currently available drugs often have extreme price volatility, low availability or unwanted side effects. Researchers will conduct a small clinical trial to evaluate the use of a new drug clevidipine to reduce blood pressure in client-owned dogs admitted to hospital. Finding a safe, affordable alternative drug that is readily available may help improve survival of critically ill canine patients requiring urgent care for heart failure. 

Study ID
D20CA-822
Study Status
Complete
Start Date
09/01/2019
Grant amount awarded
$10,640
Grant recipient
University of California/Davis
Study country
United States
Investigator
Catherine T. Gunther-Harrington, DMV
Study category
Cardiovascular